


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on August 28, 2003


Glenn P. Ladwig, Patent Attorney

1051
INFORMATION DISCLOSURE
STATEMENT
Examining Group 1651
Patent Application
Docket No. USF-T173CXC1
Serial No. 09/914,508



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Vera Afremova
Art Unit : 1651
Applicant : Beerelli Seshi
Serial No. : 09/914,508
Filed : November 7, 2001
Confirm. No. : 8090
For : Human Mesenchymal Progenitor Cell

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.


This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

09/04/2003 NROCHA1 00000022 190065 09914508

01 FC:1806 180.00 DA

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO/SB/08 (2 pages); copies of references cited therein.



SEP 02 2003

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/914,508
(use as many sheets as necessary)				Filing Date	November 7, 2001
Sheet	1	of	2	First Named Inventor	Beerelli Seshi
				Group Art Unit	1651
				Examiner Name	Vera Afremova
				Attorney Docket Number	USF-T173CXC1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
U1		10/263,419		Seshi (patent application)	10-03-2002	All
U2		5,942,225		Bruder et al.	08-24-1999	All
U3		6,010,696		Caplan et al.	01-04-2000	All
U4		5,733,542		Haynesworth et al.	03-31-1998	All
U5		5,486,359		Caplan et al.	01-23-1996	All
U6						
U7						
U8						
U9						
U10						
U11						
U12						
U13						
U14						
U15						
U16						
U17						

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴			
						T ⁶
F1						
F2						
F3						
F4						
F5						
F6						
F7						
F8						
F9						
F10						

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

O P E
SEP 02 2003

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Please type a plus sign (+) inside this box →

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Application Number	09/914,508
Filing Date	November 7, 2001
First Named Inventor	Beerelli Seshi
Group Art Unit	1651
Examiner Name	Vera Afremova
Attorney Docket Number	USF-T173CXC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	DEXTER, T.M. et al. "conditions Controlling the Proliferation of Haemopoietic Stem Cells In Vitro" <i>J. Cell. Physiol.</i> , 1977, 91(3):335-344.	
	R2	GREENBERGER, J.S. "Sensitivity of corticosteroid-dependent insulin-resistant lipogenesis in marrow preadipocytes of obese-diabetic (db/db) mice" <i>Nature</i> , October 26, 1978, 275:752-754.	
	R3	SESHI, B. et al. "Human Bone Marrow Stromal Cell: Coexpression of Markers Specific for Multiple Mesenchymal Cell Lineages" <i>Blood Cells, Molecules, and Diseases</i> , June 2000, 26(3):234-246.	
	R4	SESHI, B. "Discovery of Novel Hematopoietic Cell Adhesion Molecules From Human Bone Marrow Stromal Cell Membrane Protein Extracts by a New Cell-Blotting Technique" <i>Blood</i> , May 1994, 83(9):2399-2409.	
	R5	BORDIGNON, C. et al. "Cell Therapy: Achievements and Perspectives" <i>Haematologica</i> , 1999, 84:1110-1149.	
	R6	GARTNER, S. and H.S. KAPLAN "Long-term culture of human bone marrow cells" <i>Proc. Natl. Acad. Sci. USA</i> , August 1980, 77(8):4756-4759.	
	R7	DEXTER, T.M. et al. "Long-Term Marrow Culture: An Overview of Techniques and Experience" in <i>Long-Term Bone Marrow Culture</i> , Wright, D.G. et al., Eds., 1984, pp. 57-96.	
	R8	MARINI, F. et al. "Mesenchymal Stem Cells (MSC) from Patients with Chronic Myelogenous Leukemia (CML) Patients can be Transduced with Common Gene Transfer Vectors at High Efficiency, and are Genotypically Normal" Abstract from American Society of Hematology 42 nd Annual Meeting, Part 1. December 1-5, 2000. San Francisco, Ca.	
	R9	KEATING, A. et al. "Effect of Different Promoters on Expression of Genes Introduced into Hematopoietic and Marrow Stromal Cells by Electroporation" <i>Exp. Hematol.</i> , 1990, 18:99-102.	
	R10		
	R11		
	R12		
	R13		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.